Key Points
- ANI Pharmaceuticals VP Meredith Cook sold 500 shares at an average price of $73.59, generating $36,795 under a pre-arranged Rule 10b5-1 trading plan. She retained 73,424 shares, and has also sold 500 shares in each of the prior two months.
- ANI Pharmaceuticals recently reported quarterly EPS of $2.21, beating estimates of $2.04, while revenue rose 25.8% year over year to $266.04 million. The company’s shares opened at $70.84, near their 52-week low of $69.58.
- Analyst sentiment is mixed, with three Buy ratings and four Holds; the consensus rating is Hold with a $99.60 price target. Institutional investors own 76.05% of the company.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the transaction, the vice president directly owned 73,424 shares in the company, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total value of $35,395.00.
- On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $75.48, for a total value of $37,740.00.
ANI Pharmaceuticals Stock Down 3.7%
NASDAQ ANIP opened at $70.84 on Wednesday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 52 week low of $69.58 and a 52 week high of $97.00. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 2.37 and a beta of 0.50. The company has a fifty day moving average of $74.11 and a two-hundred day moving average of $78.04.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business's revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth $28,406,000. Deutsche Bank AG purchased a new position in shares of ANI Pharmaceuticals during the second quarter valued at $26,775,000. William Blair Investment Management LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $21,372,000. Parkman Healthcare Partners LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $16,797,000. Finally, Bank of America Corp DE bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $15,154,000. Institutional investors own 76.05% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently commented on ANIP shares. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a report on Monday, August 10th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective for the company. Guggenheim dropped their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Oppenheimer started coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price on the stock. Finally, Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $99.60.
View Our Latest Report on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.
ANI's portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
